Ambros Therapeutics launches with $125 million to advance breakthrough therapy for rare pain disorder

The funding will support the pivotal Phase 3 clinical trial of neridronate in CRPS-1

Eli Lilly reports positive Phase 3 results for oral obesity drug Orforglipron

At one year, the drug met its primary and all key secondary endpoints, delivering significantly better weight maintenance than placebo

Lupin receives positive CHMP opinion for biosimilar Ranibizumab

Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A

Godavari Biorefineries launches US biotech arm to advance novel cancer therapies

The move strengthens GBL’s clinical-stage presence in the United States

Astellas & Pfizer report breakthrough Phase 3 results in muscle-invasive bladder cancer

The combination also outperformed chemotherapy on another important secondary endpoint

AstraZeneca India receives permission from CDSCO for Datopotamab Deruxtecan powder

The receipt of this permission paves way for the marketing of Datopotamab Deruxtecan powder for concentrate for solution for infusion 100 mg (r-DNA origin) in India

Merck’s KEYTRUDA–Padcev combo delivers survival gains in Phase 3 bladder cancer trial

FDA nod to Johnson & Johnson’s AKEEGA for aggressive prostate cancer

Patients with BRCA mutations often face aggressive disease and poor prognosis

Eli Lilly re-elects Nobel Laureate Carolyn Bertozzi to Board

Bertozzi currently serves as the Baker Family Director of Sarafan ChEM-H, Anne T. and Robert M. Bass Professor at Stanford University, and Investigator of the Howard Hughes Medical Institute

Lupin receives EIR from USFDA for Nagpur injectable facility

The EIR was issued following an inspection of the facility from September 8 to September 16, 2025